NPI: 1053385500 · BERKELEY, CA 94704 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 02/13/2006
Authorized official WINSTEL, JOHN controls 20+ related entities in our dataset. Read more
| Authorized Official | WINSTEL, JOHN (CHIEF ACCOUNTING OFFICER/TREASURER) |
| NPI Enumeration Date | 02/13/2006 |
Other providers sharing the same authorized official: WINSTEL, JOHN
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 14,100 | $896K |
| 2019 | 18,390 | $817K |
| 2020 | 17,985 | $885K |
| 2021 | 13,050 | $880K |
| 2022 | 9,335 | $584K |
| 2023 | 1,980 | $183K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 26,044 | 2,209 | $4.09M |
| A4657 | Syringe, with or without needle, each | 7,068 | 1,347 | $70K |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 20,642 | 1,336 | $53K |
| J1270 | Injection, doxercalciferol, 1 mcg | 14,652 | 1,228 | $24K |
| J1756 | Injection, iron sucrose, 1 mg | 4,422 | 1,050 | $9K |
| 83970 | 289 | 270 | $518.57 | |
| 90732 | 15 | 14 | $122.09 | |
| 82728 | 194 | 185 | $112.14 | |
| 85041 | 556 | 531 | $78.48 | |
| 83550 | 169 | 161 | $71.99 | |
| 85048 | 475 | 455 | $63.76 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 40 | 40 | $62.50 |
| 83540 | 168 | 160 | $53.33 | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 31 | 25 | $27.85 |
| J0887 | Injection, epoetin beta, 1 microgram, (for esrd on dialysis) | 45 | 25 | $0.00 |
| 90674 | 30 | 29 | $0.00 |